Philippe A. Cassier

16.8k total citations · 5 hit papers
295 papers, 7.4k citations indexed

About

Philippe A. Cassier is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Philippe A. Cassier has authored 295 papers receiving a total of 7.4k indexed citations (citations by other indexed papers that have themselves been cited), including 140 papers in Oncology, 125 papers in Pulmonary and Respiratory Medicine and 60 papers in Molecular Biology. Recurrent topics in Philippe A. Cassier's work include Sarcoma Diagnosis and Treatment (51 papers), Cancer Immunotherapy and Biomarkers (49 papers) and Gastrointestinal Tumor Research and Treatment (46 papers). Philippe A. Cassier is often cited by papers focused on Sarcoma Diagnosis and Treatment (51 papers), Cancer Immunotherapy and Biomarkers (49 papers) and Gastrointestinal Tumor Research and Treatment (46 papers). Philippe A. Cassier collaborates with scholars based in France, United States and Spain. Philippe A. Cassier's co-authors include Jean‐Yves Blay, Isabelle Ray‐Coquard, Antoîne Italiano, David Pérol, Jean‐Pierre Delord, Armelle Dufresne, Axel Le Cesne, Leisha A. Emens, Marcella Fassò and Joseph P. Eder and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Philippe A. Cassier

275 papers receiving 7.3k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas

2009 624 citations Isabelle Ray‐Coquard, Claire Cropet et al. Cancer Research profile →
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer

2018 567 citations Leisha A. Emens, Cristina Cruz et al. profile →
Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study

2022 273 citations Philippe A. Cassier, Antoîne Italiano et al. Journal of Clinical Oncology profile →
Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study

2022 240 citations Nicolas Penel, Philippe A. Cassier et al. Annals of Oncology profile →
Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

2022 144 citations Vivek Subbiah, Philippe A. Cassier et al. profile →

Peers

Countries citing papers authored by Philippe A. Cassier

Since Specialization

Citations

This map shows the geographic impact of Philippe A. Cassier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philippe A. Cassier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philippe A. Cassier more than expected).

Fields of papers citing papers by Philippe A. Cassier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philippe A. Cassier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philippe A. Cassier. The network helps show where Philippe A. Cassier may publish in the future.

Co-authorship network of co-authors of Philippe A. Cassier

This figure shows the co-authorship network connecting the top 25 collaborators of Philippe A. Cassier. A scholar is included among the top collaborators of Philippe A. Cassier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philippe A. Cassier. Philippe A. Cassier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Patients’ selection and trial matching in early-phase oncology clinical trials 2024 ·Critical Reviews in Oncology/Hematology ·Pauline Corbaux, (unknown), (unknown), Armelle Vinceneux, Hélène Vanacker, (unknown), (unknown), Capucine Baldini, Philippe A. Cassier, C. Terret, Loïc Verlingue	5
2	1024P Initial clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb, administered as single agent and in combination with pembrolizumab in patients with advanced solid tumors 2024 ·Annals of Oncology ·(unknown), (unknown), J.F. Baurain, Antoîne Italiano, Madona Sakkal, (unknown), (unknown), M. Brandely, (unknown), (unknown), Monika Semmrich, Andrés McAllister, (unknown), Philippe A. Cassier	2
3	160TiP A phase I/II study of CFT1946, a novel BIDAC degrader targeting mutant BRAF V600 solid tumors including metastatic colorectal cancer (CRC) in combination with cetuximab 2024 ·Annals of Oncology ·María Vieito, (unknown), (unknown), Ezra Y. Rosen, Jordi Rodón, Víctor Moreno, Valentina Gambardella, (unknown), Sophie Cousin, Philippe A. Cassier, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Riadh Lobbardi, Eunju Hurh, Elizabeth I. Buchbinder	0
4	612O Preliminary results from a phase I study of CFT1946, a novel BIDAC degrader in mutant BRAF V600 solid tumors 2024 ·Annals of Oncology ·María Vieito, (unknown), (unknown), Ezra Y. Rosen, Jordi Rodón, Víctor Moreno, Valentina Gambardella, (unknown), Sophie Cousin, Philippe A. Cassier, (unknown), (unknown), (unknown), (unknown), (unknown), Riadh Lobbardi, Hao Liu, Eunju Hurh, Leonard Reyno, Elizabeth I. Buchbinder	3
5	Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC. 2024 ·Journal of Clinical Oncology ·Timothy F. Burns, Konstantin H. Dragnev, Yutaka Fujiwara, Yonina R. Murciano‐Goroff, (unknown), Antoine Hollebecque, Takafumi Koyama, Philippe A. Cassier, Antoîne Italiano, Rebecca S. Heist, Ji‐Youn Han, Dustin A. Deming, Alexander I. Spira, Joshua K. Sabari, Michael Chisamore, (unknown), Aaron Chen, Melinda D. Willard, Geoffrey R. Oxnard, Natraj Reddy Ammakkanavar	22
6	Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC. 2024 ·Journal of Clinical Oncology ·Yutaka Fujiwara, Timothy F. Burns, Konstantin H. Dragnev, Yonina R. Murciano‐Goroff, (unknown), Antoine Hollebecque, Takafumi Koyama, Philippe A. Cassier, Antoîne Italiano, Rebecca S. Heist, Ji‐Youn Han, Dustin A. Deming, Alexander I. Spira, Joshua K. Sabari, Michael Chisamore, (unknown), Aaron Chen, Melinda D. Willard, Geoffrey R. Oxnard, Natraj Reddy Ammakkanavar	2
7	The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers 2024 ·Science Translational Medicine ·(unknown), Carlos Gomez‐Roca, Sylvie Chabaud, Céline Rodriguez, (unknown), (unknown), (unknown), (unknown), Isabelle Treilleux, Lauriane Eberst, C. Terret, (unknown), (unknown), David Pérol, Jean‐Pierre Delord, Christophe Caux, Bertrand Dubois, Christine Ménétrier‐Caux, Nathalie Bendriss‐Vermare, Philippe A. Cassier	32
8	MA06.03 KontRASt-01: Preliminary Safety and Efficacy of JDQ443 + TNO155 in Patients with Advanced, KRAS G12C-Mutated Solid Tumors 2023 ·Journal of Thoracic Oncology ·Marcelo V. Negrão, Philippe A. Cassier, Benjamin Solomon, Martin Schüler, (unknown), Sara Cresta, Christophe Dooms, Daniel Shao-Weng Tan, Herbert H. Loong, Alessio Amatu, (unknown), Lauren Fairchild, Laurent Sansregret, (unknown), Anna F. Farago, Byoung Chul Cho	16
9	2229P Updated safety and efficacy of selpercatinib in patients (pts) with RET-activated thyroid cancer: Data from LIBRETTO-001 2023 ·Annals of Oncology ·Lori J. Wirth, Vivek Subbiah, Francis P. Worden, Benjamin Solomon, Bruce Robinson, Julien Hadoux, (unknown), (unknown), Barbara Deschler-Baier, (unknown), (unknown), (unknown), Patricia Maeda, Alexander Drilon, Philippe A. Cassier	3
10	1684TiP PARPiPANC: A multicentric, single arm, phase II assessing niraparib as first line therapy for patients with metastatic homologous repair-deficient pancreatic cancer 2023 ·Annals of Oncology ·Philippe A. Cassier, Claire Cropet, Clélia Coutzac, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Marion Chauvenet, François Ghiringhelli, Gaël S. Roth, David Pérol	0
11	Radioresistance and genomic alterations in head and neck squamous cell cancer: Sub‐analysis of the ProfiLER protocol 2021 ·Head & Neck ·(unknown), Nicolas Magné, Jérôme Fayette, Élisabeth Daguenet, S. Racadot, P. Pommier, Benoîte Méry, Alexis Vallard, Fabien Tinquaut, Eve‐Marie Neidhardt‐Berard, Philippe A. Cassier, Valéry Attignon, Daniel Pissaloux, Qing Wang, Emilie Sohier, David Pérol, Jean‐Yves Blay, Olivier Trédan	2
12	Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial 2021 ·European Journal of Cancer ·Robin L. Jones, César Serrano, Margaret von Mehren, Suzanne George, Michael C. Heinrich, Yoon‐Koo Kang, Patrick Schöffski, Philippe A. Cassier, Olivier Mir, Sant P. Chawla, Ferry A.L.M. Eskens, Piotr Rutkowski, William D. Tap, Teresa Zhou, Maria Roche, Sebastian Bauer	85
13	Long term term follow-up of tyrosine kinase inhibitors treatments in inoperable or relapsing diffuse type tenosynovial giant cell tumors (dTGCT) 2020 ·PLoS ONE ·Mehdi Brahmi, Philippe A. Cassier, Armelle Dufresne, Sylvie Chabaud, Marie Karanian, Alexandra Meurgey, (unknown), F. Gouin, Gualter Vaz, Jérôme Garret, Marie‐Pierre Sunyach, Aurélien Dupré, Perrine Marec‐Bérard, Nadège Corradini, David Pérol, Isabelle Ray‐Coquard, Jean‐Yves Blay	9
14	Generation of an Fsp1 (fibroblast‐specific protein 1)‐Flpo transgenic mouse strain 2020 ·genesis ·Victoire Cardot‐Ruffino, Véronique Chauvet, (unknown), (unknown), Nicolas Chuvin, Roxane M. Pommier, Ulrich Valcourt, David F. Vincent, Sylvie Martel, (unknown), Bastien Kaniewski, Pierre Dubus, Philippe A. Cassier, Stéphanie Sentis, Laurent Bartholin	3
15	Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response 2019 ·Nature Cell Biology ·Camilla Salvagno, Metamia Ciampricotti, (unknown), Cheei‐Sing Hau, Antoinette van Weverwijk, Seth B. Coffelt, Kelly Kersten, Kim Vrijland, Kevin Kos, Thomas Ulas, Ji‐Ying Song, Chia-Huey Ooi, Dominik Rüttinger, Philippe A. Cassier, Jos Jonkers, Joachim L. Schultze, Carola H. Ries, Karin E. de Visser	122
16	Abstract 2986: Atezolizumab in metastatic TNBC (mTNBC): Long-term clinical outcomes and biomarker analyses 2017 ·Cancer Research ·Peter Schmid, Cristina Cruz, Fadi S. Braiteh, Joseph P. Eder, Sara M. Tolaney, Irene Kuter, Rita Nanda, Cathie T. Chung, Philippe A. Cassier, Jean‐Pierre Delord, Michael S. Gordon, Yijin Li, Bo Liu, Carol O’Hear, Marcella Fassò, Luciana Molinero, Leisha A. Emens	92
17	A Retrospective Multicentric Study of Ewing Sarcoma Family of Tumors in Patients Older Than 50: Management and Outcome 2017 ·Scientific Reports ·(unknown), Antoîne Italiano, Valérie Laurence, Nicolas Penel, Audrey Lardy-Cléaud, Olivier Mir, Christine Chevreau, François Bertucci, Emmanuelle Bompas, L. Chaigneau, (unknown), Thomas Ryckewaert, Sarah Dumont, Pierre Méeus, Dominique Ranchère, Jean‐Yves Blay, Philippe A. Cassier	8
18	A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas 2016 ·Clinical Cancer Research ·Jeffrey R. Infante, Philippe A. Cassier, John F. Gerecitano, Petronella O. Witteveen, Rashmi Chugh, Vincent Ribrag, Abhijit Chakraborty, Alessandro Matano, Jason R. Dobson, Adam Crystal, Sudha Parasuraman, Geoffrey I. Shapiro	237
19	Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study 2014 ·Clinical Cancer Research ·Víctor Moreno, David Olmos, Carlos Gomez‐Roca, Philippe A. Cassier, Rafael Morales‐Barrera, (unknown), Elisa Gallerani, André T. Brunetto, Patrick Schöffski, Silvia Marsoni, Jan H.M. Schellens, Nicolas Penel, Emile E. Voest, Jeffrey Evans, Ruth Plummer, Richard H. Wilson, Jean Charles Soria, Josep Tabernero, Jaap Verweij, Stan B. Kaye	14
20	Trabectedin and its potential in the treatment of soft tissue sarcoma 2008 ·SHILAP Revista de lepidopterología ·Philippe A. Cassier, Armelle Dufresne, Jean‐Yves Blay, (unknown)	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact